Johnson & Johnson (NYSE: JNJ) just reported its financial results for the fourth quarter that slightly topped Street estimates. Its shares are roughly flat in premarket on Tuesday.Johnson & Johnson’s guidance for fiscal 2024Copy link to sectionThe pharmaceutical giant now forecasts its full-year sales to fall between $87.8 billion and$88.6 billion on up to $10.75 of per-share earnings. Analysts, in comparison, were at$87.9 billion and $10.68 a share, respectively. Joaquin Duato – the chief executive of Jo ...